PHF6 mutations are associated with adverse outcome in intermediate risk AML patients who are negative for FLT3 ITD and it has been suggested that mutations in PHF6 as well as other genes may be useful in stratifying this subgroup of AML patients [29]. Here, FLT3 is linked to acute myeloid leukemia.